Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Thomas Peterffy Biography and Net Worth

Chairman of Atara Biotherapeutics

Mr. Thomas Peterffy is the Chairman of Atara Biotherapeutics. He is 80 years old.

What is Thomas Peterffy's net worth?: The estimated net worth of Thomas Peterffy is at least $1.12 million as of January 27th, 2023. Mr. Peterffy owns 1,630,605 shares of Atara Biotherapeutics stock worth more than $1,120,063 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Peterffy may own. Learn More about Thomas Peterffy's net worth.
How do I contact Thomas Peterffy?: The corporate mailing address for Mr. Peterffy and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on Thomas Peterffy's contact information.
Has Thomas Peterffy been buying or selling shares of Atara Biotherapeutics?: Thomas Peterffy has not been actively trading shares of Atara Biotherapeutics during the past quarter. Learn More on Thomas Peterffy's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, Atara Biotherapeutics insiders bought shares 2 times. They purchased a total of 279,020 shares worth more than $64,384.40. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 184,801 shares worth more than $237,993.35. The most recent insider tranaction occured on March, 4th when CEO Pascal Touchon sold 24,844 shares worth more than $17,887.68. Insiders at Atara Biotherapeutics own 4.5% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 3/4/2024.

Thomas Peterffy Insider Trading History at Atara Biotherapeutics

Thomas Peterffy Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $0.69

$0.66

$0.72

50 Day Range

MA: $0.72

$0.60

$0.84

2 Week Range

Now: $0.69

$0.20

$3.02

Volume

697,332 shs

Average Volume

2,668,992 shs

Market Capitalization

$81.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69